John D. Quisel, the Chief Executive Officer of Disc Medicine, Inc. (NASDAQ:IRON), recently sold shares of the company’s common stock. According to the SEC filing, Quisel sold a total of 12,791 shares on December 16, 2024, with prices ranging from $64.6586 to $67.198 per share. The total value of these transactions amounted to approximately $844,314.
In addition to these sales, Quisel exercised stock options, acquiring 12,791 shares at a price of $1.01 per share. Following these transactions, Quisel now directly owns 72,065 shares of Disc Medicine.
The trades were conducted under a Rule 10b5-1 trading plan, which had been adopted earlier in the year, on July 2, 2024.
In other recent news, Disc Medicine has been in the spotlight with several significant updates. The company received favorable feedback from the FDA on its phase 3 trial for bitopertin, a treatment for erythropoietic protoporphyria (EPP). This has led to a series of upgrades in stock targets from Scotiabank (TSX:BNS), BMO Capital Markets, Jefferies, and H.C. Wainwright. Raymond (NS:RYMD) James notably elevated Disc Medicine's stock to a Strong Buy.
The positive outlook from these firms reflects confidence in Disc Medicine's clinical progress and its potential impact on the treatment landscape. Disc Medicine also reported promising results from a Phase 1b study of DISC-0974, showing significant reduction in hepcidin levels and improvement in iron mobilization and hemoglobin levels in patients with non-dialysis-dependent chronic kidney disease and anemia.
The company announced a public stock offering of approximately $178 million to advance research and clinical development of its product candidates. On the personnel front, Disc Medicine welcomed Dr. Rahul Rajan Kaushik as Chief Technical Officer and Dr. Steve Caffé as Chief Regulatory Officer, both with over two decades of experience in the pharmaceutical industry. These recent developments underscore Disc Medicine's continuous efforts to advance its clinical trials and operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.